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Summary A total of 161 previously untreated patients with FIGO stage III or IV epithelial ovarian cancer
were randomised after surgery to receive six courses of either carboplatin 400 mg m2 alone (Arm A) or
carboplatin 300mg m-2 with chlorambucil 10 mg day-' for 7 days (Arm B). The median progression free
survival (PFS) was similar: arm A: 45 weeks; arm B: 61 weeks (P = 0.830). Multivariate Cox regression
analysis showed that the extent of residual disease and performance status were the most important prognostic
factors for PFS.
Fifty-two per cent of patients received dose escalations based on nadir blood counts, ahd 89% of all dose
adjustments were made according to protocol. Failure to achieve a significant degree of leucopenia was
associated with worse progression free survival (P<0.001). A total of 29.4% of patients fall into this category.
The median survival was similar in both arms, i.e. 75 weeks. It is unlikely that there is any major clinical
advantage to adding chlorambucil to single agent carboplatin for the management of advanced ovarian cancer,
but whether used in combination or a single agent, the dose of carboplatin should be sufficient to cause at
least grade I leucopenia. This may best be achieved by determining the initial dose based on renal function,
and then adjusting subsequent doses according to nadir blood counts.
For the past decade the treatment of advanced ovarian
cancer has generally comprised maximal debulking surgery
followed by combination chemotherapy. Cisplatin has been
the most active single agent. At a dose of 100mgm-2 cis-
platin every 3 or 4 weeks the clinical complete and partial
response rates exceed 50% and the pathological complete
remission rate is around 30% in patients who have received
no prior chemotherapy or radiotherapy. Many clinicians
judge the most effective treatment for the majority of patients
to be a combination chemotherapy regimen using cisplatin at
the maximally tolerated dose, usually 100 mg m-2 (Ozols,
1985). A large randomised Italian study has shown a higher
response rate for combination chemotherapy with cisplatin,
adriamycin and cyclophosphamide compared with cisplatin
alone, although no survival differences were observed, per-
haps because of cross-over between the treatment arms
(GICOG, 1987).
Cisplatin is associated with considerable toxicity. This has
led some workers to question the practice of treating the
majority of women (especially those with bulk residual
disease) with cisplatin, since no overall survival benefit has
been demonstrated when compared with single agent chlor-
ambucil (Williams et al., 1985). However, these analyses are
complicated by the use of cisplatin as second-line therapy at
the time of relapse (Dembo, 1986).
The platinum analogue carboplatin appears to have equi-
valent anti-tumour activity to cisplatin, but is better
tolerated. Renal and neurological toxicity have not been
associated with carboplatin at standard dose, although hae-
matological toxicity, particularly thrombocytopenia is more
marked than with cisplatin (Evans et al., 1983). A recent
study compared carboplatin at 400mgm-2 (with provision
for dose escalation according to the blood count on the day
of treatment) with cisplatin 100 mg m-2, both given monthly
(Mangioni et al., 1989). No clinically important difference in
progression-free or overall survival was seen in the two arms,
but in the carboplatin arm there was less nephrotoxicity and
more, but rarely troublesome, myelosuppression.
Several studies have suggested that a dose-response rela-
tionship exists for cisplatin (Ozols et al., 1985; Hryniuk,
1987), and the same is likely to apply to carboplatin. If
carboplatin is to be used in combination with other myelo-
suppressive agents, a reduction in dose is inevitably neces-
sary, and the impact of this on overall efficacy is uncertain
(McGuire & Abeloff, 1989). A Dutch study comparing a four
drug combination including carboplatin with the same drugs
and cisplatin found little difference in response (Ten Bokkel
Huinink et al., 1987) and a collaborative study of the South-
Western Oncology Group (SWOG) likewise showed similar
efficacy for carboplatin and cisplatin when combined with
cyclophosphamide (Alberts et al., 1989). However, Edmon-
son and colleagues showed recently that carboplatin with
cyclophosphamide gave substantially inferior progression free
survival than cisplatin with cyclophosphamide, but in this
study only 150 mg m2 carboplatin could be given with the
dose of 1 g m-2 of cyclophosphamide (Edmonson et al.,
1989).
We chose to combine carboplatin with chlorambucil. There
is no evidence that any particular alkylating agent is more
effective than any other in ovarian cancer (Young et al.,
1974). Chlorambucil has been extensively tested in ovarian
cancer giving an overall response rate of 50% (Ozols &
Young, 1984) and the same overall survival when compared
prospectively with cisplatin (Williams et al., 1984). It has the
advantage that it is well tolerated, does not cause alopecia
nor the gastrointestinal or bladder toxicity associated with
cyclophosphamide. Our pilot study has shown that carbo-
platin 300 mg m- could safely be combined with chloram-
bucil 10 mg daily for 7 days (Harding et al., 1988).
The randomised study reported here was designed to
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answer the question, is there a clinically significant difference
in treatment results between the use ofcarboplatin as a single
agent at full dose and its use in combination with other
myelosuppressive agents, when a reduction in carboplatin
dose is inevitable? Women with surgically treated, advanced
(FIGO Stage III and IV) epithelial ovarian cancer were
eligible for the study. Patients were randomised to receive six
cycles of either carboplatin alone at a dose of 400 mgm
every 28 days or carboplatin 300 mgm2 intravenously on
day 1 with 10 mg chlorambucil for 7 days every 28 days. The
dose of carboplatin was escalated or reduced depending on
the interval blood counts. The two treatments were assessed
in terms of objective response rate, progression-free survival
and overall survival. Toxicity in the two arms was also
compared.
Patients and methods
Patient selection
Eligible patients with stage III and IV ovarian carcinoma
were entered in the study from five centres, all university
teaching hospitals. Eligibility criteria included histological
proof of epithelial ovarian adenocarcinoma, FIGO stage III
or IV disease, age < 75 years, performance status <2; ade-
quate bone marrow, renal and hepatic function (wbc ) 4 x
109 1-, platelets > 100 x 109 1l'; creatinine clearance >60 ml
min '; bilirubin <2 x upper limit of normal); no previous
chemotherapy or radiotherapy; no previous malignancy except
adequately treated carcinoma in situ of the cervix or basal
cell cancer of skin.
Histology was classified according to the WHO classifica-
tion (Serov et al., 1973). The degree of tumour differentiation
was based on the percentage of undifferentiated cells present
and the degree of anaplasia and classified as well different-
iated (Broder's grade 1), moderate (Broder's grade 2) or poor
(Broder's grade 3 and 4).
The study received permission from the Ethical Committees
of the participating hospitals and each patient gave informed
consent.
Surgical staging andprocedures
The extent of disease before entry to the study was deter-
mined by surgical exploration. Tumour was debulked to the
maximum extent deemed safe by the surgeon. The amount of
residual disease and its size and location were noted at the
end of exploratory laparotomy. Total abdominal hysterec-
tomy, bilateral salpingo-oophorectomy and infra-colic omen-
tectomy were done whenever possible.
Randomisation procedure
The study was a multicentre, randomised open trial. Patients
were randomised after surgery by telephone call to the West
of Scotland Clinical Trials Office. Random permuted blocks
of length six were used for randomisation. Patients were
stratified before randomisation according to institution
(Glasgow - Belfast, or Dundee or Aberdeen) and according
to the maximum diameter of residual disease (<2 cm or
>2 cm). Other possible prognostic factors (e.g. age, perfor-
mance status, histological grading, etc.) were recorded but
not used during randomisation.
Treatment plan and dose modifications
Patients were randomised to receive six courses of either
carboplatin alone at 400 mg m-2 (Arm A) or carboplatin
300 mg m 2 intravenously with chlorambucil 10 mg daily for
7 days starting 24 h after the carboplatin (Arm B). Chemo-
therapy began as soon as wound healing was secure. The
carboplatin was given over 30min in 250ml 5% dextrose.
The majority of patients received prophylactic antiemetic
therapy. Subsequent courses of treatment were given at 28
day intervals providing that the total white count on the day
of treatment was at least 3.0 x 1091-, and platelets at least
100 x 109 1-. If these values were not reached, treatment was
delayed for 1 week. If treatment was postponed for longer
than 2 weeks because of continuous myelosuppression (i.e.
more than 6 weeks between cycles) protocol therapy was
stopped.
The full blood count was measured at weekly intervals and
the dose for second and subsequent courses modified accord-
ing to the nadir count in the preceding cycle. Treatment
delay alone did not lead to alteration in dose. If the nadir
white blood count was >4 x 109 1-' and platelets > 100 x
109 1` the dose of carboplatin was increased to 500 mg m-2
in Arm A and 375 mgm-2 in Arm B, but the dose of
chlorambucil was unchanged. This dose was used for all
further courses unless the nadir white cell count after dose
escalation fell to <1 x 1091- or platelets <25 x 1091`
when the carboplatin dose reverted to 400 mgm-2 and
300 mg m-2 respectively. If, following treatment with 400 mg
m 2 carboplatin in Arm A or 300 mg m 2 carboplatin and 7
days of chlorambucil in Arm B, the nadir white cell count
was <1 x I09 lI-I or the platelet count was <25 x 109 l1-'the
dose of carboplatin was reduced to 300 mg m-2 in Arm A,
and in Arm B the dose of carboplatin was reduced to
225 mgm2 and chlorambucil to 10mg daily for 5 days. If
the nadir after dose reduction was still low (white cell count
<1 x 1091- or platelets <25 x 1091-i) the dose of carbo-
platin was further reduced to 225 mg m-2 in the single agent
arm and in the combination arm chlorambucil was stopped
and carboplatin given at a dose of 225 mgm2. If a dose
reduction had been necessary no subsequent increase in dose
was allowed.
Treatment and toxicity and response assessment
All patients had a chest radiograph, serum biochemical
screen and full blood count, creatinine clearance, an
abdominal and pelvic ultrasound scan and documentation of
the dimensions of tumour masses prior to starting chemo-
therapy. Patients were evaluated by physical and gynaeco-
logical examination each month, when renal and hepatic
function, performance status and toxicity were also recorded.
Tumour response was assessed by clinical examination,
abdominal and pelvic ultrasound and appropriate radiog-
raphs after three and six cycles of treatment. Toxicity was
recorded according to the recommendations of WHO (WHO
Handbook, 1979).
Protocol therapy consisted of six cycles of the allocated
treatment. Patients who developed clinical evidence of pro-
gressive disease stopped protocol treatment. Rising CA125
alone - 'biochemical progression' was not considered suffi-
cient for the patient to discontinue treatment. Those patients
in whom the treatment interval exceeded 6 weeks (or 8 weeks
if interval debulking surgery was performed) stopped proto-
col treatment.
Clinical response was assessed using standard criteria for
complete and partial response, stable disease and progression
(WHO Handbook, 1979). 'Pathological' response data were
obtained in those patients undergoing post-chemotherapy
surgery, but this was not obligatory.
Further treatment
Patients who achieved a complete clinical response, or com-
plete pathological response if they had a second look laparo-
tomy, received no further treatment unless relapse occurred.
Patients with persistent disease, or those who stopped proto-
col treatment for any reason, received further treatment at
their clinician's discretion.
Statistical methods
We aimed to accrue 100 patients to each arm. With long-
term follow-up these numbers would have given an 80%
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survival, e.g. from 16 to 24 months. This was considered to
be a treatment improvement which would clearly influence
clinical practice. The number of eligible patients actually
recruited was 152 and the number of deaths observed to date
give approximately a 65% chance of detecting a 55%
improvement in median survival. The study was closed at this
point following a survival analysis of the pilot study (Hardin
et al., 1988). This resulted in an overall median survival of 16
months and investigators considered that this was substan-
tially shorter than could be achieved with optimal cisplatin
combinations.
Survival and progression free survival (PFS) were measur-
ed from time ofrandomisation, i.e. from entry into study. All
eligible patients were included in the survival and progression
free survival curves. All deaths were used for calculating
survival. The Kaplan-Meier's method was used for calculat-
ing survival curves which were terminated when five patients
were at risk. Comparison of treatments in terms of survival
and PFS were done using the Mantel-Haenszel stratified
log-rank test with size of residual disease and centre as
stratification factors.
Categorical variables were compared using Pearson's chi-
square test (with no continuity correction). Categories were
combined when necessary to make the percentage ofexpected
values less than five not greater than 20%. If this were not
possible, then Fisher's exact test was used on the appropriate
2 x 2 table. The Mann-Whitney test was used for the com-
parison of ages between the two treatment arms.
In the analysis of response, stratification according to the
size of residual disease was included and the P-values were
calculated according to the Mantel-Haenszel test.
Univariate analysis of prognostic variables was done using
the log-rank test. Techniques appropriate to the Cox's pro-
portional hazards model were used for the multivariate
analysis of prognostic variables.
Results
From April 1986 to June 1989, 161 patients entered this
study. Nine of these patients were not eligible (four in Arm
A, five in Arm B), four because review of the histology
showed they did not have ovarian cancer, five because they
had stage 1 or 2 disease. All the remaining 152 patients have
been considered for analysis. Four patients were not evalu-
able for response: one in Arm A because of early death after
two courses of treatment, two in Arm B who stopped treat-
ment because of toxicity after two and three cycles, respective-
ly (the latter patient did not return for response evaluation),
and one in Arm B who received only one course and stopped
treatment because of prolonged wound infection. Treatment
began early in most patients, a median of 14 days in Arm A
and 15 days in Arm B elapsing between operation and first
dose of chemotherapy, 90% of patients commenced treat-
ment within 1 month of operation. The cut-off date for the
analysis is December 31, 1990, median follow-up then was
180 weeks (range 140 to 250 weeks).
Characteristics of the eligible patients are shown in Table
I. Patients were stratified at entry according to the size of
residual disease and treatment centre. There were no stati-
stically significant differences in the two arms of the study in
age, performance status, stage of disease, amount of residual
disease, histology or degree of tumour differentiation. More
patients in Arm B had a radical operation, and fewer a
biopsy than in Arm A. This imbalance in surgical procedure
has little impact on the treatment comparison and the results
presented are not adjusted for it. Owing to an error in the
randomisation list more patients from Dundee were allocated
to Arm A than Arm B. Since an analysis stratified for centre
has been used here, this error -does not affect the results.
Response
Of the 152 evaluable patients, only 63 had clinically detect-
able disease at the start of treatment, i.e. could be evaluated
clinically for response according to standard criteria. Sixteen
of these patients achieved a complete remission (12 in Arm A
and 4 in Arm B). The overall clinical response in Arm A was
43.6% (17/40), whilst combination treatment gave an overall
response of 29.2% (7/27). Only 18 patients (without clinically
detectable disease at entry) had second-look laparotomy;
seven in Arm A and 11 in Arm B. Of these, four (57%) and
three (27%) respectively had a pathological complete re-
sponse. The limited response data available in this study, as
in other studies in ovarian cancer in which second-line
surgery is not obligatory, preclude any further comparative
analysis.
Toxicity
The toxicity experienced with the two regimens is shown in
Table II. This describes the worst degree of toxicity seen in
any treatment cycle. More severe leucopenia was seen with
the combination treatment than with carboplatin alone
(P = 0.010). However, no serious infections requiring intra-
venous antibiotics were seen. There was a trend towards
more thrombocytopenia in the carboplatin alone arm, but
this did not approach significance. Blood transfusions were
required by 42% of the patients receiving carboplatin and
30% of those receiving the combination (P = 0.113). No
other serious toxicities were seen. Despite the use of pro-
phylactic anti-emetics, nausea and vomiting was still a prob-
lem in some patients.
Analysis ofreceiveddose
Six courses of treatment were planned, and received by 59
patients (72.8%) in Arm A and 38 patients (53.5%) in Arm
B; this difference is statistically significant (P = 0.013).
Carboplatin was stopped early in Arm A because of progres-
sion (14 patients), excessive haematological toxicity with
failure of the blood count to recover by day 42 (six patients),
patient refusal or death from an unknown cause (one each).
Fewer patients receiving carboplatin and chlorambucil com-
pleted the treatment: in 15 cases this was due to progression,
in 15 due to haematological toxicity and in one case each due
to refusal or death from an unknown cause. The median
total dose of carboplatin in Arm A was 2,400 mg m-2 (mini-
mum 400, 25 percentile 2,000, 75 percentile 2,800, maximum
2,900): and in Arm B 1,725 mg m-2 (minimum 300, 25 per-
centile 900, 75 percentile 1,988, maximum 2,175).
Provision was made in the protocol for dose escalation in
each course according to the nadir white blood cell and
platelet counts in the preceding chemotherapy cycle. The
dose ofcarboplatin could be escalated for at least one course
in approximately 50% of patients. There was no substantial
difference in the two arms in the patterns of dose reductions
escalations or delays (Table III). Dose reductions were made
in 52 cycles, and just over one quarter ofpatients had at least
one dose reduction. A total of 62 cycles were delayed, 87%
of them because of haematological toxicity (Table III).
Survival
Figure 1 shows that there is no statistically significant differ-
ence in the PFS between the two arms. The median progres-
sion free survival for Arm A was 45 weeks and for Arm B
was 61 weeks (P = 0.830). The relative progression rate is
0.96 (95% confidence interval 0.67-1.39) and these results
are consistent with quite large treatment differences both in
favour of and against the combination arm. Figure 2 shows
survival according to the size of residual disease, again there
was little difference between the two treatments (Figure 2). A
variety of pre-treatment variables were examined to deter-
mine if they had any individual association with PFS: the
results for the whole patient group are shown in Table IV.
Only size of residual disease (P =0.0002), performance status
(P =0.004) and FIGO stage (P = 0.004) showed any signifi-
cant association with PFS. A multivariate Cox regression
analysis showed that prognosis was mainly determined by278 E.M. RANKIN et al.
performance status (0/1 vs 2) and size of residual disease;
once these were allowed for, FIGO stage did not affect the
outcome.
Table I Patient characteristics and treatment
Carboplatin Carboplatin
Characteristics alone chlorambucil P-value
Eligiblefor study n = 81 n = 71
Age (yr) median 58 55 0.142
range 29-75 21 -74
ECOG performance status
0 42.0% (34) 33.8% (24) 0.570
1 43.2% (35) 47.9% (34)
2 14.8% (12) 18.1% (13)
FIGO stage III 79.0% (64) 76.1% (54) 0.663
IV 21.0% (17) 23.9% (17)
Surgicalprocedure
BSO + h + Oa 18.5% (15) 25.4% (18) 0.066
BSO + ob 12.4% (10) 25.4% (18)
Lesser operations 46.9% (38) 36.3% (26)
Biopsy alone 22.2% (18) 12.7% (9)
Residual tumour
<2cm 38.3% (31) 32.4% (23) 0.450
>2 cm 61.7% (50) 67.6% (48)
Histological type
Serous 80.3% (65) 64.8% (46) 0.105
Mucinous 8.6% (7) 12.7% (9)
Clear cell 6.2% (5) 7.0% (5)
Endometriodc 1.2% (1) 8.5% (6)
Othere 3.7% (3) 7.0% (5)
Differentiation
Wellc 8.6% (7) 2.8% (2) 0.371
Moderatec 27.2% (22) 22.5% (16)
Poor 54.3% (44) 62.0% (44)
Unknown 9.9% (8) 12.7% (9)
Centre
Aberdeen 19.8% (16) 18.3% (13) 0.150
Belfast 17.3% (14) 9.9% (7)
Dundee 21.0% (17) 12.7% (9)
Glasgow 42.0% (34) 59.2% (42)
aBilateral salpingo-oophorectomy, total hysterectomy and omentec-
tomy. bBilateral salpingo-oophorectomy and omentectomy (in a pro-
portion ofthese women the uterus had been removed at an earlier date
for other indications). 'These categories combined for calculating the
P-values.
Table III Patterns of dose escalations, reductions and treatment
delays
Carboplatin Carboplatin and
alone chlorambucil
(81)' (71)a P-value
Dose escalations
Escalated 56.8% (46) 47.9% (34) 0.273
Never escalated 43.2% (35) 52.1% (37)
Dose reductions
Reduced 28.4% (23) 26.8% (19) 0.822
Never reduced 71.6% (58) 73.2% (52)
Dose delays
Delayed 29.6% (24) 40.9% (29) 0.148
Never delayed 70.4% (57) 59.1% (42)
aNumber of patients.
o
Time (weeks)
Figure 1 Progression-free
A JM8 + chlorambucil
* JM8 alone
survival according to treatment arm.
No. at risk No. progressed
71 62
81 70
White cell counta
0
1
2
3b
4b
Platelet counta
0
1
2
3
4
Nausea and vomiting
0
1
2
3
4
Carboplatin alone
8.2% (6)C
31.5% (23)
46.6% (34)
13.7% (10)
0.0% (0)
27.8% (20)
16.7% (12)
20.8% (15)
13.9% (10)
20.8% (15)
6.2% (5)
8.6% (7)
31.2% (26)
44.4% (36)
8.6% (7)
chlorambucil
9.5% (6)
11.1% (7)
47.6% (30)
28.6% (18)
3.2% (2)
P= 0.010
37.1% (23)
11.3% (7)
27.4% (17)
14.5% (9)
9.7% (6)
P=0.304
5.6% (4)
8.5% (6)
40.9% (29)
39.4% (28)
5.6% (4)
P= 0.823
An analysis ofprogression free survival in terms of average
haematological toxicity experienced by the patient was con-
ducted. Actual nadir WBC and platelet counts for each cycle
were 'used to calculate the overall average nadir values for
each patient. In this analysis patients were first stratified
according to the number of courses of chemotherapy they
received; the intention of this was to remove any possible
confusion of the comparison as a result of patients in the
different haematological toxicity categories having received a
different number of courses of chemotherapy and therefore
having had different opportunites to achieve adequate myelo-
suppression. The analysis was then repeated adjusting for the
two previously identified major prognostic-factors (perform-
ance status and extent of residual disease) by including these
as co-variates in the proportional hazards model (Table V).
Patients whose average level of leucopenia did not exceed
grade 0 had a worse outcome than those achieving higher
grades (see Figure 3). A similar observation is seen with
thrombocytopenia, but this does not achieve statistical signi-
ficance. When leucopenia and thrombocytopenia are con-
sidered together in a multivariate analysis, the effect of
thrombocytopenia is diminished, suggesting that leucopenia
is the more important prognostic factor. Almost identical
results are obtained if analysis is restricted to those patients
who received at least three cycles.
The median disease-free survival in those with a clinical
complete remission, i.e. patients with clinically measurable
disease at the start of treatment, was 74 weeks (95% C.I.
Table II Toxicity of treatment (worst toxicity recorded)
Carboplatin and
aInformation on blood counts is only used forpatients who had these
recorded onallcourses, forpatients receiving <fourcourses; onatleast
four courses, for patients receiving >five courses. bThese categories
combined for calculating the P-value. cNumber ofpatients.JM8, MYELOSUPPRESSION AND OVARIAN CANCER 279
ci
ci
ci
CA
CA
ci
0.
Time (weeks)
Figure 2 Progression-free survival in relation to the largest
cross-sectional tumour diameter before initiation of chemo-
therapy. 0, residual disease >2 cm, carboplatin alone. Median
PFS 41 weeks; 95% C.I. 28-48 weeks; A, residual disease
>2 cm, carboplatin and chlorambucil. Median PFS 33 weeks,
95% C.I. 23-65 weeks; *, residual disease<2cm, carboplatin
alone. Median PFS 61 weeks, 95% C.I. 41-106 weeks; A,
residual disease <2cm, carboplatin and chlorambucil. Median
PFS 92 weeks; 95% C.I. 61-? weeks. Relative progression rate
(carboplatin and chlorambucil vs carboplatin alone) = 0.96
(P=0.830). 95% C.I. for relative progression rate=0.67-1.39.
Table IV Univariate analysis of association between pretreatment
variables and progression-free survival
Log-rank
Pretreatment characteristics P-value
Extent of residual disease (<2 cm vs > 2 cm) 0.0002
ECOG performance status (0/1 vs 2) 0.004
FIGO Stage (III vs IV) 0.004
Differentiation (well vs moderate vs poor) 0.110
Histological type (serous vs mucinous vs clear cell 0.756
vs other)
Age (<50 vs > 50 years) 0.421
Table V Association between average haematological toxicity (WHO
grade) and progression-free survival
WHO grade No. ofpatients P-valueb P-valuec
White cell counta 0 vs 1/2/3 40 vs 96 <0.0001 <0.0001
Plateletsa 0 vs 1/2/3 109 vs 25 0.056 0.052
aInformation on blood counts is only used forpatients who had these
recorded: on all courses, for patients receiving <four courses; on at
least four courses, for patients receiving >five courses. bThe P-value
obtained after stratifying for the number of cycles received. cThis
P-value is obtained after stratifying for the number of cycles received
andincluding performance status and extent of residual disease in the
proportional hazards model.
35-101 weeks). The median disease-free survival in the seven
patients with pathological complete remission was 98 weeks.
The overall survival in the two groups was similar
(P = 0.552) with the same median survival at 75 weeks as
shown in Figure 4. Again the wide 95% confidence intervals
of 0.77 to 1.64 for relative death rate indicate that quite large
real survival differences between the treatment arms cannot
be excluded. The amount of residual disease present before
chemotherapy again influenced the long-term outcome as
shown in Figure 5.
Time (weeks)
Figure 3 Progression-free survival in relation to mean recorded
white cell count nadir (WHO grade). *, Grade 2/3; A, Grade 1
*, Grade 0.
co
cL
U1)
ai)
0L
'vA
Time (weeks)
Figure 4 Overall survival according to treatment arm.
No. at risk No. death
A JM8 + chlorambucil 71 57
* JM8 alone 81 63
Tumour progression was the cause of 104 of the 120
patients who have died, eight died of unrelated causes and in
seven the cause of death is unknown. These seven patients
died at home or were lost to follow-up. There was one
treatment related death in a patient who was conservatively
managed in a peripheral hospital for intestinal perforation
and haemorrhage occurring during the nadir of her first
course whn the platelet count was 20 x 109/l-'.
Discussion
Carboplatin was introduced in Great Britain in April 1986 as
an alternative to cisplatin with the objective of offering equal
efficacy with less toxicity (Calvert et al., 1982). To date the
sample sizes in the studies comparing carboplatin and cis-
a)
a1)
C
0
c)
0
CD
a1)
cr) C.)
ci)
a)
00
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a1)
co
c)
a1)
C.)
G)
Time (weeks)
Figure 5 Overall survival in relation to the largest cross-sectional
tumour diameter prior to chemotherapy. 0, Residual disease
> 2 cm, carboplatin alone. Median survival 59 weeks; 95% C.I.
51-93 weeks; A, Residual disease> 2 cm, carboplatin and chlor-
ambucil. Median 51 weeks, 95% C.I. 37-72 weeks;*, residual
disease<2 cm, carboplatin alone. Median 107 weeks, 95% C.I.
75-193 weeks; A, residual disease <2 cm, carboplatin and chlor-
ambucil. Median survival 151 weeks; 95% C.I. 94-? weeks.
Relative death rate (carboplatin and chlorambucil vs carboplatin
alone) = 1.12 (P = 0.552). 95% C.I. for relative death rate=
0.77- 1.64.
platin either as single agent or in combination are too small
to show a definitive equivalence or otherwise between the two
agents (Alberts et al., 1989; Edmonson et al., 1989; Ten
Bokkel Huinink et al., 1987). Overviews of several random-
ised trials, which use a meta-analysis technique, can help to
address the issue of limited numbers. Such a study has
recently been conducted in ovarian cancer (Advanced Ovar-
ian Cancer Trialists Group, 1991), and it points to the impor-
tance of long-term follow-up in comparative trials involving
carboplatin.
Since randomised studies indicate that, at least in terms of
response, the combination of an alkylating agent with cis-
platin is superior to cisplatin alone (GICOG, 1987), a key
issue for the future use of carboplatin will be its activity
when combined with an alkylating agent. Our own pilot sudy
had shown that a combination of carboplatin 300 mgm-'
with ch-lorambucil 10 mg d x 7 days was well tolerated, and
although dose reduction was sometimes required, dose esca-
lation was possible in some patients (Harding et al., 1988).
In the randomised study reported here the dose for each
cycle was based on the nadir blood count in the preceding
cycle and both escalation and reduction were possible. Pro-
vision was made for only one escalation step. Further esca-
lation of carboplatin would have been possible in some
patients, as indicated by the fact that 31% of patients assess-
able for haematological toxicity only ever had mild (Grade 1
or less) myelosuppression. The interpatient variation in hand-
ling of carboplatin was idiosyncratic and did not correlate
with age or disease stage (data not shown). No correlation
was seen in the study reported here between received dose
intensity for carboplatin and response, progression-free sur-
vival or overall survival.
We have observed a clear association between leucopenia
and progression-free survival, and this is independent of
other prognostic factors, i.e. performance status and extent
of residual disease. While it is conceivable that patients prone
to leucopenia have an inherently better prognosis, intuitively
it is logical to suggest that interpatient variations in drug
handling may affect outcome. A recent analysis of 767
patients treated with carboplatin for ovarian cancer has con-
firmed the relationship between tumour response and indivi-
dual patient pharmacokinetics, i.e. area under the curve
(Egorin et al., 1991). For these reasons it would be appro-
priate in patients receiving carboplatin alone or in combina-
tion to adjust the dose as necessary to achieve adequate
myelosuppression (at least Grade 1) with each course of
treatment. Adjustments of dose based on the criteria used in
this study are simple to operate and easy to apply. Several
other formulae are available for carboplatin alone (Egorin et
al., 1985; Fish et al., 1987) or in combination (Calvert et al.,
1989; Belani et al., 1989). We suggest that the individual
variation in carboplatin handling can best be accommodated
by determining the initial dose of carboplatin used alone or
in combination on the basis of renal function (Calvert et al.,
1989) and adjusting subsequent doses according to the nadir
blood count.
One other study in ovarian cancer has shown that myelo-
suppression during chemotherapy confers an improved sur-
vival probability (GG.COSA, 1986). In that study which
compared combination vs sequential therapy with chloram-
bucil and cisplatin, myelosuppression (defined as white cell
count <2.5 x109 -' and/or platelets <100 x 109 1-) acted
as an independent variable in the Cox multivariate analysis
with a P value of <0.001.
The dose of carboplatin used in either arm of our study is
in line with that used in the other quoted studies. Mangioni
and colleagues incorporated provision for dose escalation
based on the blood count on the day of treatment, to a
maximum of 500mgm-2 carboplatin by 50 mgm-2 steps
(Mangioni et al., 1989). In that study 38% patients had a
dose escalation and 32% reduction. In our study, where the
number of dose adjustments was similar in both arms and
where the nadir blood count was used to guide the dose,
50% patients had at least one dose escalation and 25% a
dose reduction.
In conclusion, we have compared carboplatin alone with a
combination of carboplatin and chlorambucil in a random-
ised study in patients with Stage III and IV ovarian cancer.
We found no statistically significant difference in the pro-
gression-free survival or overall survival between the two
treatments. It therefore seems unlikely that there is any major
advantage (i.e. median survival difference of 30% or more) to
adding an alkylating agent, at least chlorambucil, to single
agent carboplatin for the management of this disease. The
amount of residual disease at the start of chemotherapy and
the performance status were the most important predictors
for progression-free survival. Although the median overall
survival seen in both arms in this study of 75 weeks, is less
than that which can be achieved with cisplatin-based com-
bination therapy, proper comparisons can only be made on
prospective randomised studies with long-term follow-up.
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